Triple-negative Breast Cancer and HR+/HER2- BC

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Triple-negative Breast Cancer and HR+/HER2- BC trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT04348747

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative B…

This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER…

United States23 participantsStarted 2022-12-19

Treatment: Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab

All recent trials (2 shown)

Active — Not RecruitingPhase 2

NCT05445908

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectab…

China175 participantsStarted 2022-08-17

Treatment: SKB264, KL-A167